1
|
Heublein S, Pfisterer J, du Bois A, Anglesio M, Aminossadati B, Bhatti I, Sehouli J, Wimberger P, Schochter F, Hilpert F, Hillemanns P, Kalder M, Schroeder W, Mahner S, Burges A, Canzler U, Gropp-Meier M, Jackisch C, Harter P, Kommoss S, Marmé F. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7. J Transl Med 2024; 104:100321. [PMID: 38154497 DOI: 10.1016/j.labinv.2023.100321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 12/18/2023] [Accepted: 12/20/2023] [Indexed: 12/30/2023] Open
Abstract
With more novel drugs being approved for the treatment of ovarian carcinoma, the question remains to what extent patients benefit from antiangiogenic treatment with bevacizumab, either in combination with poly-(ADP-ribose) polymerase inhibitors or as single-agent maintenance. As fibroblast growth factor receptors and their ligands (FGFRs/FGFs) are key players in angiogenic signaling and have been linked to resistance to several drugs, we investigated the prognostic or predictive potential of FGFs/FGFRs signaling in the context of bevacizumab treatment within the prospective phase III AGO-OVAR11/ICON-7 study. FGFR1, FGFR2, FGFR3, FGFR4, FGF1, and FGF19 gene expressions were determined in 380 ovarian carcinoma tumor samples collected from German centers in the multicenter phase III AGO-OVAR11 trial/ICON-7 trial. All patients received carboplatin and paclitaxel, administered every 3 weeks for 6 cycles, and were randomized to bevacizumab. Expressions of FGFR1, FGFR2, FGF1, and FGF19 were associated with progression-free survival in both uni- and multivariate (FGFR1: HR, 1.6, P < .001; FGFR2: HR, 1.6, P = .002; FGF1: HR, 2.3, P < .001; and FGF19: HR, 0.7; P = .007) analysis. A signature built by FGFR1, FGFR4, and FGF19 defined a subgroup (n = 62) of patients that derived the greatest bevacizumab-associated improvement of progression-free survival (HR, 0.3; P = .004). In this exploratory analysis of a prospective randomized phase III trial, we provide evidence that the expression of FGFRs/FGFs might have independent prognostic values. An FGFR/FGF-based gene signature identified in our study appears to predict long-term benefit from bevacizumab. This observation is hypothesis-generating and requires validation on independent cohorts.
Collapse
Affiliation(s)
- Sabine Heublein
- Department of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
| | | | - Andreas du Bois
- Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany
| | - Michael Anglesio
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Behnaz Aminossadati
- Coordinating Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany
| | - Irfan Bhatti
- National Center for Tumor Diseases Heidelberg, Heidelberg, Germany
| | - Jalid Sehouli
- Department of Gynecology and Gynecologic Oncology, University Berlin, Charité, Berlin, Germany
| | - Pauline Wimberger
- Department of Gynecology and Obstetrics, Carl-Gustav-Carus University, TU Dresden and National Cancer Center (NCT Dresden), Dresden, Germany; Department of Gynecology and Obstetrics, University Duisburg-Essen, Essen, Germany
| | - Fabienne Schochter
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - Felix Hilpert
- Oncologic Therapy Center Hospital Jerusalem, UKHS Kiel, Hamburg, Germany
| | - Peter Hillemanns
- Department of Gynecology and Obstetrics, Medical School Hannover, Hannover, Germany
| | - Matthias Kalder
- Department of Gynecology and Obstetrics, Philips-University Marburg, Marburg, Germany
| | | | - Sven Mahner
- Department of Gynecology, University Hamburg Eppendorf, Hamburg, Germany; Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximillians-University Munich, Munich, Germany
| | - Alexander Burges
- Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximillians-University Munich, Munich, Germany
| | - Ulrich Canzler
- Department of Gynecology and Obstetrics, Carl-Gustav-Carus University, TU Dresden and National Cancer Center (NCT Dresden), Dresden, Germany
| | - Martina Gropp-Meier
- Oberschwabenklinik, Department of Gynecology, Krankenhaus St. Elisabeth, Ravensburg, Germany
| | - Christian Jackisch
- Department of Gynecology and Obstetrics, SANA-Klinikum Offenbach, Offenbach, Germany
| | - Philipp Harter
- Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany
| | - Stefan Kommoss
- Department of Gynecology and Obstetrics, University Hospital Tuebingen, Tübingen, Germany; Department of Gynecology and Obstetrics, Klinikum Schwäbisch-Hall, Schwäbisch-Hall, Germany
| | - Frederik Marmé
- Department of Gynecology and Obstetrics, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| |
Collapse
|
2
|
Ji JX, Cochrane DR, Negri GL, Colborne S, Spencer Miko SE, Hoang LN, Farnell D, Tessier-Cloutier B, Huvila J, Thompson E, Leung S, Chiu D, Chow C, Ta M, Köbel M, Feil L, Anglesio M, Goode EL, Bolton K, Morin GB, Huntsman DG. The proteome of clear cell ovarian carcinoma. J Pathol 2022; 258:325-338. [PMID: 36031730 PMCID: PMC9649886 DOI: 10.1002/path.6006] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2022] [Revised: 08/05/2022] [Accepted: 08/26/2022] [Indexed: 01/19/2023]
Abstract
Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics for 192 cases of CCOC and compared these with other epithelial ovarian carcinoma subtypes. Our results showed distinct proteomic differences in CCOC compared with other epithelial ovarian cancer subtypes including alterations in lipid and purine metabolism pathways. Furthermore, we report potential clinically significant proteomic subgroups within CCOC, suggesting the biologic plausibility of stratified treatment for this cancer. Taken together, our results provide a comprehensive understanding of the CCOC proteomic landscape to facilitate future understanding and research of this disease. © 2022 The Pathological Society of Great Britain and Ireland.
Collapse
Affiliation(s)
- Jennifer X Ji
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Dawn R Cochrane
- Department of Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada
| | - Gian Luca Negri
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, University of British Columbia, Vancouver, BC, Canada
| | - Shane Colborne
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, University of British Columbia, Vancouver, BC, Canada
| | - Sandra E Spencer Miko
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, University of British Columbia, Vancouver, BC, Canada
| | - Lynn N Hoang
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | - David Farnell
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Basile Tessier-Cloutier
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Jutta Huvila
- Department of Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada
- Department of Biomedicine, University of Turku, Turku, Finland
| | - Emily Thompson
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Samuel Leung
- Genetic Pathology Evaluation Center, Vancouver, BC, Canada
| | - Derek Chiu
- Genetic Pathology Evaluation Center, Vancouver, BC, Canada
| | - Christine Chow
- Genetic Pathology Evaluation Center, Vancouver, BC, Canada
| | - Monica Ta
- Genetic Pathology Evaluation Center, Vancouver, BC, Canada
| | - Martin Köbel
- Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
| | - Lucas Feil
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
| | - Michael Anglesio
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
| | - Ellen L Goode
- Department of Health Science Research, Mayo Clinic, Rochester, MN, USA
| | - Kelly Bolton
- Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
| | - Gregg B Morin
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, University of British Columbia, Vancouver, BC, Canada
- Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada
| | - David G Huntsman
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Department of Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
3
|
Barnes D, Mohammad N, Hoang L, Anglesio M, Hollis RL, Gourley C, Stuart HC, Carey MS, Stuart GC. Multisite gynecologic endometrioid adenocarcinomas: Can mutation profiling be used to distinguish synchronous primary cancers from metastases? Gynecol Oncol Rep 2022; 44:101076. [PMID: 36299398 PMCID: PMC9589011 DOI: 10.1016/j.gore.2022.101076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2022] [Revised: 09/30/2022] [Accepted: 10/03/2022] [Indexed: 11/26/2022] Open
Abstract
It is well recognized that some patients with endometrioid gynecological cancers have tumors arising in multiple sites (ovary, endometrium, and endometriosis) at the time of diagnosis. Molecular analysis has helped discern whether these multisite cancers represent synchronous primary tumors or alternatively metastatic disease. We present a complex case of a patient with endometrioid carcinomas arising in multiple sites. We discuss the use of mutation profiling to discern clonality and highlight how this information may inform the clinical management of such cases.
Collapse
Affiliation(s)
- Dominique Barnes
- Department of Obstetrics and Gynecology, University of British Columbia, Canada,Corresponding author at: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia, 2775 Laurel Street, 6th Floor, DHCC, Vancouver, BC V5Z 1M9, Canada.
| | - Nissreen Mohammad
- Department of Pathology, Vancouver General Hospital and the University of British Columbia, Canada
| | - Lien Hoang
- Department of Pathology, Vancouver General Hospital and the University of British Columbia, Canada
| | - Michael Anglesio
- Department of Obstetrics and Gynecology, University of British Columbia, Canada
| | - Robert L. Hollis
- The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, MRC Institute of Genetics and Cancer, University of Edinburgh, UK
| | - Charlie Gourley
- The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, MRC Institute of Genetics and Cancer, University of Edinburgh, UK
| | - Heather C. Stuart
- Department of Surgery, Vancouver General Hospital, and the University of British Columbia, Canada
| | - Mark S. Carey
- Department of Obstetrics and Gynecology, University of British Columbia, Canada
| | - Gavin C.E. Stuart
- Department of Obstetrics and Gynecology, University of British Columbia, Canada
| |
Collapse
|
4
|
Hanker LC, El-Balat A, Drosos Z, Kommoss S, Karn T, Holtrich U, Gitas G, Graeser-Mayer M, Anglesio M, Huntsman D, Rody A, Gevensleben H, Hoellen F. Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer. J Cancer Res Clin Oncol 2021; 147:1421-1430. [PMID: 33660008 PMCID: PMC8021516 DOI: 10.1007/s00432-021-03558-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 02/04/2021] [Indexed: 12/15/2022]
Abstract
Purpose Sphingosine-kinase-1 (SPHK1) is a key enzyme of sphingolipid metabolism which is involved in ovarian cancer pathogenesis, progression and mechanisms of drug resistance. It is overexpressed in a variety of cancer subtypes. We investigated SPHK1 expression as a prognostic factor in epithelial ovarian cancer patients. Methods Expression analysis of SPHK1 was performed on formalin-fixed paraffin-embedded tissue from 1005 ovarian cancer patients with different histological subtypes using immunohistochemistry. Staining intensity of positive tumor cells was assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival. Results In our ovarian cancer collective, high levels of SPHK1 expression correlated significantly with complete surgical tumor resection (p = 0.002) and lower FIGO stage (p = 0.04). Progression-free and overall survival were further significantly longer in patients with high-grade serous ovarian cancer and overexpression of SPHK1 (p = 0.002 and p = 0.006, respectively). Conclusion Our data identify high levels of SPHK1 expression as a potential favorable prognostic marker in ovarian cancer patients. Supplementary Information The online version of this article (10.1007/s00432-021-03558-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- L C Hanker
- Department of Gynecology and Obstetrics, University Hospital Luebeck, Luebeck, Germany.
| | - A El-Balat
- Department of Obstetrics and Gynecology, Goethe-University Frankfurt, Frankfurt, Germany
| | - Z Drosos
- Department of Gynecology and Obstetrics, University Hospital Luebeck, Luebeck, Germany
| | - S Kommoss
- Department of Woman's Health, Tuebingen University Hospital, Tuebingen, Germany
| | - T Karn
- Department of Obstetrics and Gynecology, Goethe-University Frankfurt, Frankfurt, Germany
| | - U Holtrich
- Department of Obstetrics and Gynecology, Goethe-University Frankfurt, Frankfurt, Germany
| | - G Gitas
- Department of Gynecology and Obstetrics, University Hospital Luebeck, Luebeck, Germany
| | - M Graeser-Mayer
- Evangelical Hospital Bethesda, Lower Rhine Breast Center, Moenchengladbach, Germany
| | - M Anglesio
- Department of Molecular Oncology, BCCA Cancer Research Centre, Vancouver, Canada
| | - D Huntsman
- Department of Molecular Oncology, BCCA Cancer Research Centre, Vancouver, Canada
| | - A Rody
- Department of Gynecology and Obstetrics, University Hospital Luebeck, Luebeck, Germany
| | - H Gevensleben
- Institute of Pathology, University Hospital Bonn, Bonn, Germany
| | - F Hoellen
- Department of Gynecology and Obstetrics, University Hospital Luebeck, Luebeck, Germany
| |
Collapse
|
5
|
Feil L, Senz J, Ta M, Huvila J, Greif K, Krämer B, Brucker S, Grimm C, Bartl T, Zeder-Gösz C, Schmöckel E, Trillsch F, Mahner S, Kommoss F, Lehr HA, Wiedemeyer K, Köbel M, Staebler A, Anglesio M, Kommoss S. Molecular stratification of clear cell ovarian carcinomas. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | - J Senz
- University of British Columbia, OVCARE/Dep. of Obstetrics and Gynecology
| | - M Ta
- University of British Columbia, OVCARE/Dep. of Obstetrics and Gynecology
| | - J Huvila
- University of British Columbia, OVCARE/Dep. of Obstetrics and Gynecology
| | - K Greif
- Institut für Pathologie und Neuropathologie, Abteilung Allgemeine Pathologie und Pathologische Anatomie
| | | | | | - C Grimm
- Universitätsklinik für Frauenheilkunde, Abteilung für allgemeine Gynäkologie und gynäkologische Onkologie
| | - T Bartl
- Universitätsklinik für Frauenheilkunde, Abteilung für allgemeine Gynäkologie und gynäkologische Onkologie
| | - C Zeder-Gösz
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - E Schmöckel
- Pathologisches Institut der Ludwig-Maximilians-Universität
| | - F Trillsch
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - S Mahner
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - F Kommoss
- Institut für Pathologie im Medizin Campus Bodensee
| | - H.-A Lehr
- Institut für Pathologie im Medizin Campus Bodensee
| | - K Wiedemeyer
- Department of Pathology and Laboratory Medicine, University of Calgary
| | - M Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary
| | - A Staebler
- Institut für Pathologie und Neuropathologie, Abteilung Allgemeine Pathologie und Pathologische Anatomie
| | - M Anglesio
- University of British Columbia, OVCARE/Dep. of Obstetrics and Gynecology
| | | |
Collapse
|
6
|
Grube M, Krämer P, Chiu D, Bosse T, Scheunhage D, Koebel M, Singh N, Manchanda R, Hammond R, Heitz F, Harter P, du Bois A, Ataseven B, Neudeck N, Beschorner C, Fischer A, Greif K, Krämer B, Brucker S, Talhouk A, Anglesio M, Staebler A, Kommoss S. Immunhistochemische Expression von L1CAM in endometrioiden Ovarialkarzinomen – Ein neuer prognostischer Marker? Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Grube
- Universitätsfrauenklinik Tübingen
| | - P Krämer
- Universitätsfrauenklinik Tübingen
| | - D Chiu
- Department of Obstetrics and Gynecology, University of British Columbia
| | - T Bosse
- Leiden University Medical Center
| | | | - M Koebel
- Department of Pathology and Laboratory Medicine, University of Calgary
| | - N Singh
- Dept of Cellular Pathology, BartsHealth NHS Trust
| | - R Manchanda
- Dept of Cellular Pathology, BartsHealth NHS Trust
| | - R Hammond
- Dept of Cellular Pathology, BartsHealth NHS Trust
| | | | | | | | | | - N Neudeck
- Institut für Pathologie, Universitätsklinikum Tübingen
| | - C Beschorner
- Institut für Pathologie, Universitätsklinikum Tübingen
| | - A Fischer
- Institut für Pathologie, Universitätsklinikum Tübingen
| | - K Greif
- Institut für Pathologie, Universitätsklinikum Tübingen
| | - B Krämer
- Universitätsfrauenklinik Tübingen
| | | | - A Talhouk
- Department of Obstetrics and Gynecology, University of British Columbia
| | - M Anglesio
- Department of Obstetrics and Gynecology, University of British Columbia
| | - A Staebler
- Institut für Pathologie, Universitätsklinikum Tübingen
| | | |
Collapse
|
7
|
Martins FC, Couturier DL, Paterson A, Karnezis AN, Chow C, Nazeran TM, Odunsi A, Gentry-Maharaj A, Vrvilo A, Hein A, Talhouk A, Osorio A, Hartkopf AD, Brooks-Wilson A, DeFazio A, Fischer A, Hartmann A, Hernandez BY, McCauley BM, Karpinskyj C, de Sousa CB, Høgdall C, Tiezzi DG, Herpel E, Taran FA, Modugno F, Keeney G, Nelson G, Steed H, Song H, Luk H, Benitez J, Alsop J, Koziak JM, Lester J, Rothstein JH, de Andrade JM, Lundvall L, Paz-Ares L, Robles-Díaz L, Wilkens LR, Garcia MJ, Intermaggio MP, Alcaraz ML, Brett MA, Beckmann MW, Jimenez-Linan M, Anglesio M, Carney ME, Schneider M, Traficante N, Pejovic N, Singh N, Le N, Sinn P, Ghatage P, Erber R, Edwards R, Vierkant R, Ness RB, Leung S, Orsulic S, Brucker SY, Kaufmann SH, Fereday S, Gayther S, Winham SJ, Kommoss S, Pejovic T, Longacre TA, McGuire V, Rhenius V, Sieh W, Shvetsov YB, Whittemore AS, Staebler A, Karlan BY, Rodriguez-Antona C, Bowtell DD, Goode EL, Høgdall E, Candido Dos Reis FJ, Gronwald J, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, Fasching PA, Crawford R, Deen S, Menon U, Huntsman DG, Köbel M, Ramus SJ, Pharoah PDP, Brenton JD. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. Br J Cancer 2020; 123:793-802. [PMID: 32555365 PMCID: PMC7463007 DOI: 10.1038/s41416-020-0900-0] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2020] [Revised: 03/14/2020] [Accepted: 04/29/2020] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarker in epithelial ovarian cancer in a large population-based study. METHODS Tumours from 5400 patients from a multicentre observational, prospective cohort study of the Ovarian Tumour Tissue Analysis Consortium were used to evaluate associations between immunohistochemical PTEN patterns and overall survival time, age, stage, grade, residual tumour, CD8+ tumour-infiltrating lymphocytes (TIL) counts, expression of oestrogen receptor (ER), progesterone receptor (PR) and androgen receptor (AR) by means of Cox proportional hazard models and generalised Cochran-Mantel-Haenszel tests. RESULTS Downregulation of cytoplasmic PTEN expression was most frequent in ENOC (most frequently in younger patients; p value = 0.0001) and CCOC and was associated with longer overall survival in HGSOC (hazard ratio: 0.78, 95% CI: 0.65-0.94, p value = 0.022). PTEN expression was associated with ER, PR and AR expression (p values: 0.0008, 0.062 and 0.0002, respectively) in HGSOC and with lower CD8 counts in CCOC (p value < 0.0001). Heterogeneous expression of PTEN was more prevalent in advanced HGSOC (p value = 0.019) and associated with higher CD8 counts (p value = 0.0016). CONCLUSIONS PTEN loss is a frequent driver in ovarian carcinoma associating distinctly with expression of hormonal receptors and CD8+ TIL counts in HGSOC and CCOC histotypes.
Collapse
MESH Headings
- Adenocarcinoma, Clear Cell/enzymology
- Adenocarcinoma, Clear Cell/mortality
- Adenocarcinoma, Clear Cell/pathology
- Age Factors
- Biomarkers, Tumor/biosynthesis
- Biomarkers, Tumor/genetics
- Carcinoma, Ovarian Epithelial/enzymology
- Carcinoma, Ovarian Epithelial/genetics
- Carcinoma, Ovarian Epithelial/mortality
- Carcinoma, Ovarian Epithelial/pathology
- Cohort Studies
- Down-Regulation
- Female
- Gene Knockout Techniques
- Humans
- Middle Aged
- Neoplasm Staging
- Ovarian Neoplasms/enzymology
- Ovarian Neoplasms/genetics
- Ovarian Neoplasms/mortality
- Ovarian Neoplasms/pathology
- PTEN Phosphohydrolase/biosynthesis
- PTEN Phosphohydrolase/deficiency
- PTEN Phosphohydrolase/genetics
- Prospective Studies
- Receptors, Androgen/biosynthesis
- Receptors, Estrogen/biosynthesis
- Receptors, Progesterone/biosynthesis
- Tissue Array Analysis
- Tumor Suppressor Proteins/biosynthesis
- Tumor Suppressor Proteins/deficiency
Collapse
Affiliation(s)
- Filipe Correia Martins
- Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, England
- Experimental Medicine Initiative, University of Cambridge, Cambridge, England
- Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, England
| | - Dominique-Laurent Couturier
- Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, England
| | - Anna Paterson
- Department of Histopathology, Addenbrookes Hospital, Cambridge, England
| | - Anthony N Karnezis
- Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA, USA
| | - Christine Chow
- OVCARE, Vancouver Coastal Health Research Centre, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada
| | - Tayyebeh M Nazeran
- Department of Molecular Oncology and Department of Pathology and Laboratory Medicine, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada
| | - Adekunle Odunsi
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA
| | | | - Aleksandra Vrvilo
- Department of Ob/Gyn, Oregon Health & Science University, Portland, OR, USA
| | - Alexander Hein
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - Aline Talhouk
- Department of Molecular Oncology and Department of Pathology and Laboratory Medicine, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
- Department of Molecular Oncology, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada
| | - Ana Osorio
- Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Andreas D Hartkopf
- Department of Women's Health, Tübingen University Hospital, Tübingen, Germany
| | - Angela Brooks-Wilson
- Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Anna DeFazio
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia
- Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia
| | - Anna Fischer
- Institute of Pathology, Tübingen University Hospital, Tübingen, Germany
| | - Arndt Hartmann
- Institute of Pathology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | | | - Bryan M McCauley
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - Chloe Karpinskyj
- MRC CTU, Institute of Clinical Trials and Methodology, University College London, London, England
| | - Christiani B de Sousa
- Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
| | - Claus Høgdall
- Department of Gynaecology, Rigshospitalet, University Hospital Copenhagen, Blegdamsvej 9, 2100, København, Denmark
| | - Daniel G Tiezzi
- Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
| | - Esther Herpel
- NCT Tissue Bank, National Center for Tumour Diseases, Heidelberg, Germany
- Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - Florin Andrei Taran
- Department of Women's Health, Tübingen University Hospital, Tübingen, Germany
| | - Francesmary Modugno
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Gary Keeney
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - Gregg Nelson
- Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
| | - Helen Steed
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Royal Alexandra Hospital, Edmonton, AB, Canada
| | - Honglin Song
- Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, England
| | - Hugh Luk
- Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA
| | - Javier Benitez
- Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Jennifer Alsop
- Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, England
| | | | - Jenny Lester
- Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Joseph H Rothstein
- Department of Population Health Science and Policy and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jurandyr M de Andrade
- Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
| | - Lene Lundvall
- Department of Gynaecology, Rigshospitalet, University Hospital Copenhagen, Blegdamsvej 9, 2100, København, Denmark
| | - Luis Paz-Ares
- Spanish National Cancer Research Center, CNIO Lung Cancer Clinical Research Unit, New York, NY, USA
| | - Luis Robles-Díaz
- Familial Cancer Unit and Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Lynne R Wilkens
- Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA
| | - Maria J Garcia
- Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Maria P Intermaggio
- School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia
| | - Marie-Lyne Alcaraz
- Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, England
| | - Mary A Brett
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
| | - Matthias W Beckmann
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | | | - Michael Anglesio
- OVCARE, Vancouver Coastal Health Research Centre, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada
- Department of Molecular Oncology and Department of Pathology and Laboratory Medicine, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
| | - Michael E Carney
- John A. Burns School of Medicine, Department of Obstetrics and Gynecology, University of Hawaii, Honolulu, HI, USA
| | - Michael Schneider
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - Nadia Traficante
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
- Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia
| | - Nadja Pejovic
- School of Medicine, St. Louis University, St. Louis, MO, 63103, USA
| | - Naveena Singh
- Department of Cellular Pathology, Barts Health National Health Service Trust, London, England
| | - Nhu Le
- Cancer Control Research, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Peter Sinn
- Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - Prafull Ghatage
- Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
| | - Ramona Erber
- Institute of Pathology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - Robert Edwards
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Robert Vierkant
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - Roberta B Ness
- University of Texas School of Public Health, Houston, TX, USA
| | - Samuel Leung
- OVCARE, Vancouver Coastal Health Research Centre, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada
| | - Sandra Orsulic
- Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Sara Y Brucker
- Department of Women's Health, Tübingen University Hospital, Tübingen, Germany
| | - Scott H Kaufmann
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - Sian Fereday
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
- Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia
| | - Simon Gayther
- Cedars-Sinai Center for Bioinformatics and Functional Genomics, Los Angeles, CA, USA
| | - Stacey J Winham
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - Stefan Kommoss
- Department of Women's Health, Tübingen University Hospital, Tübingen, Germany
| | - Tanja Pejovic
- Department of Ob/Gyn, Oregon Health & Science University, Portland, OR, USA
| | - Teri A Longacre
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
| | - Valerie McGuire
- Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA
| | - Valerie Rhenius
- Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, England
| | - Weiva Sieh
- Department of Population Health Science and Policy and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Yurii B Shvetsov
- Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA
- Department of Pathology, University of Melbourne, Melbourne, VIC, Australia
| | - Alice S Whittemore
- Department of Health Research and Policy and Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA
| | - Annette Staebler
- Institute of Pathology, Tübingen University Hospital, Tübingen, Germany
| | - Beth Y Karlan
- Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Cristina Rodriguez-Antona
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid, Madrid, Spain
| | - David D Bowtell
- Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Parkville, VIC, Australia
- The Garvan Institute, Sydney, NSW, Australia
| | - Ellen L Goode
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - Estrid Høgdall
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
- Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
- Cancer Genomics Program, Research Department, Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Francisco J Candido Dos Reis
- Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
| | - Jacek Gronwald
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Kirsten B Moysich
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - Linda E Kelemen
- Department of Public Health Sciences, Medical University of South Carolina and Hollings Cancer Center, Charleston, SC, USA
| | - Linda S Cook
- Division of Epidemiology, Biostatistics and Preventative Medicine, University of New Mexico, Albuquerque, NM, USA
| | - Marc T Goodman
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Peter A Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
- David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, 90095, USA
| | - Robin Crawford
- Division of Oncology, Addenbrookes Hospital, Cambridge, England
| | - Suha Deen
- Department of Histopathology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, England
| | - Usha Menon
- MRC CTU, Institute of Clinical Trials and Methodology, University College London, London, England
| | - David G Huntsman
- OVCARE, Vancouver Coastal Health Research Centre, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada
- Department of Molecular Oncology and Department of Pathology and Laboratory Medicine, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada
- Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
- Department of Molecular Oncology, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada
| | - Martin Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
| | - Susan J Ramus
- School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia
- The Garvan Institute, Sydney, NSW, Australia
| | - Paul D P Pharoah
- Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, England.
- Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Worts Causeway, Cambridge, England.
- Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, England.
| | - James D Brenton
- Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, England.
- Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, England.
- Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, England.
| |
Collapse
|
8
|
Krämer P, Talhouk A, Bosse T, Heitz F, Singh N, Kommoss F, Brucker S, McAlpine J, Kommoss S, Koebel M, Anglesio M. Abstract B20: Endometrial cancer molecular risk stratification in endometrioid ovarian cancers: A novel application of precision medicine. Clin Cancer Res 2020. [DOI: 10.1158/1557-3265.ovca19-b20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objective: Endometrioid ovarian carcinoma (ENOC) is associated with a generally more favorable prognosis compared to other ovarian carcinoma histotypes. Nonetheless, patients are still treated with a “one size fits all” approach. While tumor staging offers some stratification, the development of personalized treatment concepts remains elusive. Our group has recently validated the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), to distinguish clinically relevant prognostic groups amongst endometrial carcinomas. ENOC shares risk factors, genomics, and histology with its endometrial counterpart. The aim of our study was to apply and test ProMisE on ENOC.
Methods: ProMisE was applied to 509 ENOC after biomarker-assisted review of ENOC histotype. Cases were aligned into low-risk POLE mutant (POLE), moderate-risk mismatch repair deficient (MMRd), high-risk p53 abnormal (p53abn), and a final moderate-risk category lacking these biomarkers (p53wt). Kaplan-Meier and multivariate survival analysis were performed.
Results: 4% of cases were POLE, 16% MMRd, 71% p53wt, and 10% p53abn. Groups showed distinct progression-free and overall survival (p <0.001), near identical to profiles of endometrial cancers. 5-year PFS was 54% in p53abn, 82% in MMRd, 85% in p53wt, and 100% in POLEmut cases. Median overall survival was reached in p53 mutant cases only. ProMisE classes of ENOC were independent of stage and residual disease in multivariable analysis.
Conclusion: ProMisE risk classification provides additional prognostic information in a large cohort of ENOC. Our findings support introduction of ProMisE-stratified treatment strategies to improve patient care across ENOC. Further, ENOC may benefit from parallel efforts under investigation in endometrial carcinoma.
Citation Format: Pauline Krämer, Aline Talhouk, Tjalling Bosse, Florian Heitz, Naveena Singh, Felix Kommoss, Sara Brucker, Jessica McAlpine, Stefan Kommoss, Martin Koebel, Michael Anglesio. Endometrial cancer molecular risk stratification in endometrioid ovarian cancers: A novel application of precision medicine [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr B20.
Collapse
Affiliation(s)
| | - Aline Talhouk
- 2University of British Columbia, Vancouver, BC, Canada,
| | | | | | - Naveena Singh
- 5Barts Health National Health Service Trust, London, United Kingdom,
| | - Felix Kommoss
- 6Heidelberg University Hospital, Heidelberg, Germany,
| | - Sara Brucker
- 1Tuebingen University Hospital, Tuebingen, Germany,
| | | | | | | | | |
Collapse
|
9
|
Talhouk A, George J, Wang C, Goode E, Ramus S, Doherty J, Bowtell D, Anglesio M. Abstract A03: PrOTYPE (Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE): The development and validation of a clinical-grade consensus classifier for the molecular subtypes of high-grade serous tubo-ovarian cancer. Clin Cancer Res 2020. [DOI: 10.1158/1557-3265.ovca19-a03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Gene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC) are distinguished by differential immune and stromal infiltration and may provide opportunities for targeted therapies. Integration of molecular subtypes into clinical trials has been hindered by inconsistent subtyping methodology.
Methods: Adopting two independent approaches, we derived and internally validated algorithms for molecular subtype prediction from gene-expression array data in 1,650 tumors. We applied resulting models to assign labels to 3829 HGSOCs from the Ovarian Tumor Tissue Analysis (OTTA) consortium evaluated on NanoString. Using the labeled NanoString data, we developed, confirmed, and validated a minimal gene set, clinical-grade test and prediction tool. We also used the OTTA dataset to evaluate associations between molecular subtype, biologic, and clinical features.
Findings: The locked-down test included a model with 55 genes that predicted HGSOC molecular subtype with >95% accuracy. Subtype varied between primary and metastatic site taken at the time of primary surgery, and was significantly associated with age, stage, CD8+ lymphocyte infiltration, residual disease, and outcome. In multivariable models, molecular subtypes lose their prognostic significance in the presence of risk factors such as residual disease and BRCA1/2 germline mutations.
Interpretation: We validated the Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE, or PrOTYPE, following the Institute of Medicine guidelines for the development of omics-based tests. This simple-to-use, cost-effective, fully defined, and locked-down clinical-grade assay will facilitate molecular subtype stratification into clinical trial design. PrOTYPE will allow for objective assessment of HGSOC molecular subtype predictive value in precision medicine applications.
Citation Format: Aline Talhouk, Joshy George, Chen Wang, Ellen Goode, Susan Ramus, Jennifer Doherty, David Bowtell, Michael Anglesio, OTTA Consortium. PrOTYPE (Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE): The development and validation of a clinical-grade consensus classifier for the molecular subtypes of high-grade serous tubo-ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr A03.
Collapse
Affiliation(s)
- Aline Talhouk
- 1University of British Columbia, Vancouver, BC, Canada,
| | | | | | | | - Susan Ramus
- 4University of New South Wales, Sydney, NSW, Australia,
| | | | - David Bowtell
- 6Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | | | | |
Collapse
|
10
|
Hanker LC, Drosos Z, Kommoss S, Karn T, Holtrich U, Graeser-Mayer M, Anglesio M, El-Balat A, Rody A, Gevensleben H. Expression of Sphingosine-Kinase 1 (SPHK1) as a prognostic factor in ovarian cancer. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- LC Hanker
- University Luebeck, Department of Gynecology and Obstetrics, Luebeck, Deutschland
| | - Z Drosos
- University Luebeck, Department of Gynecology and Obstetrics, Luebeck, Deutschland
| | - S Kommoss
- Tuebingen University Hospital, Department of Woman's Health, Tuebingen, Deutschland
| | - T Karn
- Goethe University Frankfurt, Department of Obstetrics and Gynecology, Frankfurt, Deutschland
| | - U Holtrich
- Goethe University Frankfurt, Department of Obstetrics and Gynecology, Frankfurt, Deutschland
| | - M Graeser-Mayer
- Bethesda Hospital, Department of Gynecology, Moenchengladbach, Deutschland
| | - M Anglesio
- BCCA Cancer Research Centre, Department of Molecular Oncology, Vancouver, Kanada
| | - A El-Balat
- Goethe University Frankfurt, Department of Obstetrics and Gynecology, Frankfurt, Deutschland
| | - A Rody
- University Luebeck, Department of Gynecology and Obstetrics, Luebeck, Deutschland
| | - H Gevensleben
- University Hospital Bonn, Institute of Pathology, Bonn, Deutschland
| |
Collapse
|
11
|
Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, Kelemen LE, Nazeran TM, Gilks CB, Harris HR, Huntsman DG, Schildkraut JM, Rossing MA, Köbel M, Doherty JA. Histotype classification of ovarian carcinoma: A comparison of approaches. Gynecol Oncol 2018; 151:53-60. [PMID: 30121132 PMCID: PMC6292681 DOI: 10.1016/j.ygyno.2018.08.016] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 08/07/2018] [Accepted: 08/13/2018] [Indexed: 11/24/2022]
Abstract
OBJECTIVE Major changes in the classification of ovarian carcinoma histotypes occurred over the last two decades, resulting in the current 2014 World Health Organization (WHO) diagnostic criteria that recognize five principal histotypes: high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous carcinoma. We assessed the impact of these guidelines and use of immunohistochemical (IHC) markers on classification of ovarian carcinomas in existing population-based studies. METHODS We evaluated histotype classification for 2361 ovarian carcinomas diagnosed between 1999 and 2009 from two case-control studies using three approaches: 1. pre-2014 WHO ("historic") histotype; 2. Standardized review of pathology slides using the 2014 WHO criteria alone; and 3. An integrated IHC assessment along with the 2014 WHO criteria. We used Kappa statistics to assess agreement between approaches, and Kaplan-Meier survival curves and Cox proportional hazards models to evaluate mortality. RESULTS Compared to the standardized pathologic review histotype, agreement across approaches was high (kappa = 0.892 for historic, and 0.849 for IHC integrated histotype), but the IHC integrated histotype identified more low-grade serous carcinomas and a subset of endometrioid carcinomas that were assigned as high-grade serous (n = 25). No substantial differences in histotype-specific mortality were observed across approaches. CONCLUSIONS Our findings suggest that histotype assignment is fairly consistent regardless of classification approach, but that progressive improvements in classification accuracy for some less common histotypes are achieved with pathologic review using the 2014 WHO criteria and with IHC integration. We additionally recommend a classification scheme to fit historic data into the 2014 WHO categories to answer histotype-specific research questions.
Collapse
Affiliation(s)
- Lauren C Peres
- Department of Public Health Sciences, University of Virginia, 560 Ray C. Hunt Dr., P.O. Box 800765, Charlottesville, VA 22903, USA.
| | - Kara L Cushing-Haugen
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1110 Fairview Avenue N, Seattle, WA 98109, USA
| | - Michael Anglesio
- Department of Obstetrics and Gynecology, University of British Columbia, 2660 Oak Street, Vancouver, British Columbia V6H 3Z6, Canada
| | - Kristine Wicklund
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1110 Fairview Avenue N, Seattle, WA 98109, USA
| | - Rex Bentley
- Department of Pathology, Duke University Medical Center, 2301 Erwin Rd., Durham, NC 27710, USA
| | - Andrew Berchuck
- Department of Obstetrics and Gynecology, Duke University Medical Center, 25171 Morris Bldg., Durham, NC 27710, USA
| | - Linda E Kelemen
- Hollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina, 68 President St., MSC955, Charleston, SC 29425, USA
| | - Tayyebeh M Nazeran
- Department of Pathology and Laboratory Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada
| | - C Blake Gilks
- Department of Pathology and Laboratory Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada
| | - Holly R Harris
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1110 Fairview Avenue N, Seattle, WA 98109, USA
| | - David G Huntsman
- Department of Pathology and Laboratory Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada
| | - Joellen M Schildkraut
- Department of Public Health Sciences, University of Virginia, 560 Ray C. Hunt Dr., P.O. Box 800765, Charlottesville, VA 22903, USA
| | - Mary Anne Rossing
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1110 Fairview Avenue N, Seattle, WA 98109, USA
| | - Martin Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary Laboratory Services, 1403 29 St NW, Calgary, Alberta T2N 2T9, Canada
| | - Jennifer A Doherty
- Huntsman Cancer Institute and Department of Population Health Sciences, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA
| |
Collapse
|
12
|
Xia Z, Cochrane D, Anglesio M, Yang W, Alcaide M, Nazeran T, Senz J, Lum A, Bashashati A, Wang Y, Morin R, Shah S, Huntsman D. Abstract B22: Capturing L1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers as a way to track tumor development. Clin Cancer Res 2018. [DOI: 10.1158/1557-3265.ovca17-b22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Endometrioid ovarian cancer (ENOC) and clear cell ovarian cancer (CCOC) share a common precursor lesion, endometriosis (ectopic growth of uterine lining), hence the designation endometriosis-associated ovarian cancer (EAOC). Women with endometriosis have up to three-fold increased risk of developing ENOC and CCOC. Efforts have been made to look for biomarkers that can help identifying women at risk of developing cancer; however, there are currently no biomarkers that stratify risk of cancer development. We performed whole-genome sequencing (WGS) on 29 ENOC and 35 CCOC cases and observed a frequent transduction event originating from an active LINE-1 (L1) retrotransposable element in the TTC28 gene. Such event occurred in 34% (10/29) of ENOC, and 31% (11/35) of CCOC cases. L1 retrotransposons are repetitive, mobile genetic elements capable of taking downstream DNA fragments and inserting them into random genomic locations via a process called 3’ transduction. Approximately 70-100 different potentially active L1s are epigenetically silenced in normal tissues, but tend to be reactivated in cancers. We subsequently used PCR to validate these TTC28-L1 transductions, and compared their presence to single nucleotide variations (SNVs) and frameshift mutations in formalin-fixed, paraffin-embedded (FFPE) tumor tissues from different tumor sites for 4 ENOC and 3 CCOC cases. We found that these transduction events along with classical driver mutations were almost ubiquitous across the tumor sites, suggesting these L1 events likely occurred early in the malignant transformation of EAOCs.
We developed a low-input, probe-based capture assay to test the presence of TTC28-L1 transductions as an alternative method to performing WGS. Oligonucleotide probes tiling 1 kb downstream of active L1s are used to capture DNA fragments containing the transduced DNA, and the fragments are sequenced on the MiSeq next-generation sequencing platform. Analyses are performed using the Geneious software and the published bioinformatics tool Socrates, specific for detecting DNA fragments with split reads (fragments with ends aligning to different parts of the genome). We successfully validated the assay on 9 cases with WGS data: 7 EAOC cases with TTC28-L1 transductions and 2 EAOC cases without TTC28-L1 transductions. DNA extracted from frozen tumor and buffy coat (normal control) were used for each case, and FFPE tissues were used for selected cases. All reads containing the transduction events aligned to genomic coordinates corresponding to the WGS data.
While L1-mediated DNA transductions are often passenger events during tumorigenesis, our data suggest that they likely occur early in ovarian cancer tumorigenesis. Our data show that this probe-based capture assay provides an alternative method to WGS, and may be useful in detecting active 3’ transductions in novel cases to track the development of ovarian tumors.
Citation Format: Zhouchunyang Xia, Dawn Cochrane, Michael Anglesio, Winnie Yang, Miguel Alcaide, Tayyebeh Nazeran, Janine Senz, Amy Lum, Ali Bashashati, Yikan Wang, Ryan Morin, Sohrab Shah, David Huntsman. Capturing L1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers as a way to track tumor development. [abstract]. In: Proceedings of the AACR Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment; Oct 1-4, 2017; Pittsburgh, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(15_Suppl):Abstract nr B22.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Amy Lum
- 2BC Cancer Agency, Vancouver, BC, Canada,
| | | | - Yikan Wang
- 1University of British Columbia, Vancouver, BC, Canada,
| | - Ryan Morin
- 3Simon Fraser University, Burnaby, BC, Canada
| | - Sohrab Shah
- 1University of British Columbia, Vancouver, BC, Canada,
| | | |
Collapse
|
13
|
Millstein J, Budden T, Anglesio M, Talhouk A, Beeghly-Fadiel A, Berchuck A, Chenevix-Trench G, deFazio A, Fasching PA, Gayther S, García M, Goode EL, Henderson M, Konecny GE, Orsulic S, Huntsman D, Bowtell D, Doherty J, Pharoah P, Ramus SJ. A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.5583] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Joshua Millstein
- Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA
| | - Timothy Budden
- School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia
| | - Michael Anglesio
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Aline Talhouk
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Alicia Beeghly-Fadiel
- Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN
| | | | | | - Anna deFazio
- University of Sydney at Westmead Millennium Institute, Sydney, Australia
| | | | - Simon Gayther
- The Center for Bioinformatics and Functional Genomics at Cedars Sinai Medical Center, Los Angeles, CA
| | - María García
- Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO, Madrid, Spain
| | | | | | | | | | | | | | - Jennifer Doherty
- Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
| | - Paul Pharoah
- Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Susan J Ramus
- School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia
| | | |
Collapse
|
14
|
Dawson A, Fernandez ML, Anglesio M, Yong PJ, Carey MS. Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development. Ecancermedicalscience 2018; 12:803. [PMID: 29456620 PMCID: PMC5813919 DOI: 10.3332/ecancer.2018.803] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Indexed: 12/11/2022] Open
Abstract
Endometriosis is a fascinating disease that we strive to better understand. Molecular techniques are shedding new light on many important aspects of this disease: from pathogenesis to the recognition of distinct disease variants like deep infiltrating endometriosis. The observation that endometriosis is a cancer precursor has now been strengthened with the knowledge that mutations that are present in endometriosis-associated cancers can be found in adjacent endometriosis lesions. Recent genomic studies, placed in context, suggest that deep infiltrating endometriosis may represent a benign neoplasm that invades locally but rarely metastasises. Further research will help elucidate distinct aberrations which result in this phenotype. With respect to identifying those patients who may be at risk of developing endometriosis-associated cancers, a combination of molecular, pathological, and inheritance markers may define a high-risk group that might benefit from risk-reducing strategies.
Collapse
Affiliation(s)
- Amy Dawson
- Department of Obstetrics & Gynaecology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia V6Z 2K8, Canada
| | - Marta Llauradó Fernandez
- Department of Obstetrics & Gynaecology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia V6Z 2K8, Canada
| | - Michael Anglesio
- Department of Obstetrics & Gynaecology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia V6Z 2K8, Canada.,Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada
| | - Paul J Yong
- Department of Obstetrics & Gynaecology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia V6Z 2K8, Canada
| | - Mark S Carey
- Department of Obstetrics & Gynaecology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia V6Z 2K8, Canada.,Department of Surgical Oncology, BC Cancer Agency, Vancouver, British Columbia V5Z 1G1, Canada
| |
Collapse
|
15
|
Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer 2017; 123:802-813. [DOI: 10.1002/cncr.30496] [Citation(s) in RCA: 358] [Impact Index Per Article: 51.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Revised: 10/04/2016] [Accepted: 10/05/2016] [Indexed: 11/12/2022]
Affiliation(s)
- Aline Talhouk
- Department of Pathology and Laboratory Medicine; University of British Columbia and British Columbia Cancer Agency; Vancouver British Columbia Canada
| | - Melissa K. McConechy
- Department of Human Genetics; McGill University, Research Institute of the McGill University Health Network; Montreal Quebec Canada
| | - Samuel Leung
- Genetic Pathology Evaluation Center; Department of Pathology and Laboratory Medicine, University of British Columbia; Vancouver British Columbia Canada
| | - Winnie Yang
- Department of Pathology and Laboratory Medicine; University of British Columbia and British Columbia Cancer Agency; Vancouver British Columbia Canada
| | - Amy Lum
- Department of Pathology and Laboratory Medicine; University of British Columbia and British Columbia Cancer Agency; Vancouver British Columbia Canada
| | - Janine Senz
- Department of Pathology and Laboratory Medicine; University of British Columbia and British Columbia Cancer Agency; Vancouver British Columbia Canada
| | - Niki Boyd
- Department of Pathology and Laboratory Medicine; University of British Columbia and British Columbia Cancer Agency; Vancouver British Columbia Canada
| | - Judith Pike
- Department of Gynecology and Obstetrics; Division of Gynecologic Oncology, University of British Columbia; Vancouver British Columbia Canada
| | - Michael Anglesio
- Department of Pathology and Laboratory Medicine; University of British Columbia and British Columbia Cancer Agency; Vancouver British Columbia Canada
| | - Janice S. Kwon
- Department of Gynecology and Obstetrics; Division of Gynecologic Oncology, University of British Columbia; Vancouver British Columbia Canada
| | - Anthony N. Karnezis
- Department of Pathology and Laboratory Medicine; University of British Columbia and British Columbia Cancer Agency; Vancouver British Columbia Canada
| | - David G. Huntsman
- Department of Pathology and Laboratory Medicine; University of British Columbia and British Columbia Cancer Agency; Vancouver British Columbia Canada
| | - C. Blake Gilks
- Department of Pathology and Laboratory Medicine; University of British Columbia and Vancouver General Hospital; Vancouver British Columbia Canada
| | - Jessica N. McAlpine
- Department of Gynecology and Obstetrics; Division of Gynecologic Oncology, University of British Columbia; Vancouver British Columbia Canada
| |
Collapse
|
16
|
Bashashati A, Anglesio M, Wang Y, Ha G, Senz J, Yang W, Kalloger S, Prentice L, Yanagida S, Salamanca C, Soukhatcheva G, Karnezis A, Chang H, Hirst M, Mes-Mason AM, Okamoto A, Marra M, Gilks B, Shah S, Huntsman D. Abstract LB-312: The somatic mutational landscape of ovarian clear cell carcinoma and its precursor lesions. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-lb-312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Clear Cell ovarian carcinomas (CCC) represent ∼10% of ovarian carcinomas, with outcomes for high-stage cases significantly worse than the more common high-grade serous form. Response to standard chemotherapies are poor and efforts to improve treatment strategies are confounded by studies grouping ovarian histologies together, as well as a general lack of molecular background data on CCC. CCC frequently occurs in a background of endometriosis. The complete mutational landscape, the molecular basis of the transformation of endometriosis and patterns of clonal evolution in CCC are not understood.
We performed whole genome sequencing and gene expression profiling on 19 CCC to uncover candidate somatic alterations (mutations and, copy number aberrations) and measure their effect on transcriptional networks as candidates for driver mutations. We then performed targeted deep sequencing on the primary tumor samples, metastases and, from a subset of cases, adjacent or distant typical and atypical endometriosis. We used statistical modeling approaches to validate mutations, quantify the degree of clonal diversity and trace patterns of selection through oncogenic transformation.
Mutations in ARID1A and PIK3CA were by far the most frequent aberrations seen in the cohort (ARID1A: 10/19 cases; PIK3CA: 8/19 cases). The majority of ARID1A mutant cases exhibited bi-allelic loss of function. Two non-ARID1A mutant cases showed alterations in other SWI/SNF complex components. Amongst the 24 most significant candidate drivers impacting expression, five genes (PIK3CA, CTNNB1, TP53, PPP2R1A and KRAS) were known drivers. No association between PIK3CA or ARID1A status with disease stage, genomic instability, or mutation load was observed. Analysis of deep sequencing data suggested the presence of multiple clones in every case. For each case with matching precursor lesions, we observed multiple mutations in at least one such lesion. Cases with ARID1A and PIK3CA mutations always showed evidence of these mutations in their precursor lesions. The proportion of mutations from the primary tumor that were also present in precursor lesions varied widely across the cohort from approximately 10% to nearly 100%.
Our data support both ARID1A and PIK3CA mutations as early events in CCC. The pattern of endometriosis transformation could be associated with somatic mutations in all cases. This suggests that candidate tumor-initiating mutations and global- or individually- targetable features should be a focus to improve management of this disease. Finally, we suggest that patterns of mutational conservation across the series of precursor lesions presents an opportunity for early screening of endometriosis tissues as an indicator of transformation potential.
Citation Format: Ali Bashashati, Michael Anglesio, Yikan Wang, Gavin Ha, Janine Senz, Winnie Yang, Steve Kalloger, Leah Prentice, Satoshi Yanagida, Clara Salamanca, Galina Soukhatcheva, Anthony Karnezis, Hector Chang, Martin Hirst, Anne-Marie Mes-Mason, Aikou Okamoto, Marco Marra, Blake Gilks, Sohrab Shah, David Huntsman. The somatic mutational landscape of ovarian clear cell carcinoma and its precursor lesions. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-312. doi:10.1158/1538-7445.AM2014-LB-312
Collapse
Affiliation(s)
- Ali Bashashati
- 1BC Cancer Agency Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Michael Anglesio
- 2University of British Columbia, Vancouver, British Columbia, Canada
| | - Yikan Wang
- 1BC Cancer Agency Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Gavin Ha
- 2University of British Columbia, Vancouver, British Columbia, Canada
| | - Janine Senz
- 2University of British Columbia, Vancouver, British Columbia, Canada
| | - Winnie Yang
- 1BC Cancer Agency Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Steve Kalloger
- 2University of British Columbia, Vancouver, British Columbia, Canada
| | - Leah Prentice
- 1BC Cancer Agency Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Satoshi Yanagida
- 1BC Cancer Agency Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Clara Salamanca
- 2University of British Columbia, Vancouver, British Columbia, Canada
| | | | - Anthony Karnezis
- 2University of British Columbia, Vancouver, British Columbia, Canada
| | - Hector Chang
- 2University of British Columbia, Vancouver, British Columbia, Canada
| | - Martin Hirst
- 2University of British Columbia, Vancouver, British Columbia, Canada
| | | | - Aikou Okamoto
- 4The Jikei University School of Medicine, Tokyo, Japan
| | - Marco Marra
- 1BC Cancer Agency Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Blake Gilks
- 2University of British Columbia, Vancouver, British Columbia, Canada
| | - Sohrab Shah
- 1BC Cancer Agency Cancer Research Centre, Vancouver, British Columbia, Canada
| | - David Huntsman
- 2University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
17
|
Chen J, Wang Y, McConechy M, Anglesio M, Senz J, Yang W, Rosner J, Chu A, Cheng G, Morin G, Huntsman D. Abstract 544: Recurrent DICER1 hotspot mutations in endometrial cancer and their impact on microRNA biogenesis. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Alternation in genes associated with microRNA (miRNA) biogenesis pathway may lead to miRNA dysregulation, and is implicated in a variety of human malignancies. Previously our group identified recurrent somatic “hotspot” mutations (E1705, D1709, D1810, E1813) in a critical miRNA-processing gene, DICER1, in rare sex cord-stromal tumors. During miRNA biogenesis, the two RNase III domains of DICER1 form an intramolecular dimer, which leads to the cleavage of the precursor miRNA (pre-miRNA) hairpin and generate mature 5p and 3p miRNAs from 5’ and 3’ arms of the precursor hairpin respectively. Studies have shown that the hotspot mutations in the RNase IIIb metal binding domain could impair DICER1's ability to generate mature 5p miRNAs, leading to global loss of 5p miRNAs.
Recently, in collaboration with The Cancer Genome Atlas (TCGA), we identified DICER1 hotspot mutations in a small subset of endometrial cancer from TCGA cohort (6/248) as well as our own tumor bank (6/307), suggesting disruption of DICER1 is implicated in a common malignancy. We also found an additional recurrent mutation G1809R and demonstrated that it has similar detrimental effects on miRNA biogenesis as hotspot mutations through deep sequencing and realtime PCR. Using Illumina Miseq targeted resequencing and Sanger sequencing, we observed biallelic DICER1 mutations in RNase IIIb domain in some but not all cases. miRNA deep sequencing confirmed that 5p miRNAs are decreased in both cell line models and endometrial tumors with hotspot mutations. Bioinformatic analysis of RNA sequencing profiles from TCGA dataset predicted hotspot DICER1 mutations to have greater functional impact than non-hotspot DICER1 mutations on gene expression. The oncogenic properties of DICER1 hotspot mutations are currently under investigation.
Citation Format: Jiamin Chen, Yemin Wang, Melissa McConechy, Michael Anglesio, Janine Senz, Winnie Yang, Jamie Rosner, Andy Chu, Grace Cheng, Gregg Morin, David Huntsman. Recurrent DICER1 hotspot mutations in endometrial cancer and their impact on microRNA biogenesis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 544. doi:10.1158/1538-7445.AM2014-544
Collapse
Affiliation(s)
- Jiamin Chen
- 1BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Yemin Wang
- 1BC Cancer Agency, Vancouver, British Columbia, Canada
| | | | | | - Janine Senz
- 1BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Winnie Yang
- 1BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Jamie Rosner
- 2BC Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Andy Chu
- 3Genome Sciences Centre, Vancouver, British Columbia, Canada
| | - Grace Cheng
- 3Genome Sciences Centre, Vancouver, British Columbia, Canada
| | - Gregg Morin
- 3Genome Sciences Centre, Vancouver, British Columbia, Canada
| | | |
Collapse
|
18
|
Zaby K, Staebler A, Taran A, McConechy M, Rozenberg N, Huntsman D, Gilks B, Anglesio M, Brucker S, Fend F, Kommoss F, Wallwiener D, Kommoss S. Diagnostik adulter Granulosazelltumoren unter Berücksichtigung aktueller Forschungsergebnisse. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
19
|
Maaßen M, Anglesio M, Staebler A, Wallwiener D, Kommoss F, McConechy M, Karnezis A, Chang HL, Huntsman DG, Gilks CB, Brucker S, Taran FA, Kommoss S. Synchronous stage IA endometrial and ovarian carcinomas share common mutations: implications for tumour evolution and clinical staging. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
20
|
Townsend KN, Spowart JE, Huwait H, Eshragh S, West NR, Elrick MA, Kalloger SE, Anglesio M, Watson PH, Huntsman DG, Lum JJ. Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma. PLoS One 2013; 8:e82406. [PMID: 24376535 PMCID: PMC3871161 DOI: 10.1371/journal.pone.0082406] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Accepted: 10/23/2013] [Indexed: 01/08/2023] Open
Abstract
Background When T cells infiltrate the tumor environment they encounter a myriad of metabolic stressors including hypoxia. Overcoming the limitations imposed by an inadequate tumor vasculature that contributes to these stressors may be a crucial step to immune cells mounting an effective anti-tumor response. We sought to determine whether the functional capacity of tumor infiltrating lymphocytes (TIL) could be influenced by the tumor vasculature and correlated this with survival in patients with ovarian cancer. Methodology and Principal Findings In 196 high-grade serous ovarian tumors, we confirmed that the tumor vascularity as measured by the marker CD31 was associated with improved patient disease-specific survival. We also found that tumors positive for markers of TIL (CD8, CD4 and forkhead box P3 (FoxP3)) and T cell function (granzyme B and T-cell restricted intracellular antigen-1 (TIA-1)) correlated significantly with elevated vascularity. In vitro, hypoxic CD8 T cells showed reduced cytolytic activity, secreted less effector cytokines and upregulated autophagy. Survival analysis revealed that patients had a significant improvement in disease-specific survival when FoxP3 expressing cells were present in CD31-high tumors compared to patients with FoxP3 expressing cells in CD31-low tumors [HR: 2.314 (95% CI 1.049–5.106); p = 0.0377]. Patients with high vascular endothelial growth factor (VEGF) expressing tumors containing granzyme B positive cells had improved survival compared to patients with granzyme B positive cells in VEGF-low tumors [HR: 2.522 (95% CI 1.097–5.799); p = 0.0294]. Significance Overall, this data provides a rationale for developing strategies aimed at improving the adaptability and function of TIL to hypoxic tumor conditions.
Collapse
Affiliation(s)
- Katelin N. Townsend
- Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada
- Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada
| | - Jaeline E. Spowart
- Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada
- Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada
| | - Hassan Huwait
- Anatomical Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada
| | - Sima Eshragh
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Nathan R. West
- Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada
- Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada
| | - Mary A. Elrick
- Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada
- Department of Biology, University of Victoria, Victoria, British Columbia, Canada
| | - Steve E. Kalloger
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Michael Anglesio
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Peter H. Watson
- Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada
- Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - David G. Huntsman
- Centre for the Translational & Applied Genomics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Julian J. Lum
- Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada
- Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada
- Department of Biology, University of Victoria, Victoria, British Columbia, Canada
- * E-mail:
| |
Collapse
|
21
|
Kommoss S, Gilks CB, Penzel R, Herpel E, Mackenzie R, Huntsman D, Schirmacher P, Anglesio M, Schmidt D, Kommoss F. A current perspective on the pathological assessment ofFOXL2in adult-type granulosa cell tumours of the ovary. Histopathology 2013; 64:380-8. [DOI: 10.1111/his.12253] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2013] [Accepted: 08/09/2013] [Indexed: 11/29/2022]
Affiliation(s)
- Stefan Kommoss
- Department of Obstetrics and Gynaecology; Eberhard Karls Universität Tübingen; Tübingen Germany
- Department of Pathology and Laboratory Medicine; University of British Columbia; Vancouver BC Canada
| | - Cyril Blake Gilks
- Department of Pathology and Laboratory Medicine; University of British Columbia; Vancouver BC Canada
| | - Roland Penzel
- Institute of Pathology; University of Heidelberg Medical School; Heidelberg Germany
| | - Esther Herpel
- Institute of Pathology; University of Heidelberg Medical School; Heidelberg Germany
| | | | - David Huntsman
- Department of Pathology and Laboratory Medicine; University of British Columbia; Vancouver BC Canada
- Center for Translational and Applied Genomics; Vancouver BC Canada
| | - Peter Schirmacher
- Institute of Pathology; University of Heidelberg Medical School; Heidelberg Germany
| | - Michael Anglesio
- Department of Pathology and Laboratory Medicine; University of British Columbia; Vancouver BC Canada
| | | | | |
Collapse
|
22
|
Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MTY, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, Gilks B, Yip S, Huntsman DG, McAlpine JN, Shah SP. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013; 231:21-34. [PMID: 23780408 PMCID: PMC3864404 DOI: 10.1002/path.4230] [Citation(s) in RCA: 317] [Impact Index Per Article: 28.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2013] [Revised: 06/04/2013] [Accepted: 06/07/2013] [Indexed: 12/24/2022]
Abstract
High-grade serous ovarian cancer (HGSC) is characterized by poor outcome, often attributed to the emergence of treatment-resistant subclones. We sought to measure the degree of genomic diversity within primary, untreated HGSCs to examine the natural state of tumour evolution prior to therapy. We performed exome sequencing, copy number analysis, targeted amplicon deep sequencing and gene expression profiling on 31 spatially and temporally separated HGSC tumour specimens (six patients), including ovarian masses, distant metastases and fallopian tube lesions. We found widespread intratumoural variation in mutation, copy number and gene expression profiles, with key driver alterations in genes present in only a subset of samples (eg PIK3CA, CTNNB1, NF1). On average, only 51.5% of mutations were present in every sample of a given case (range 10.2-91.4%), with TP53 as the only somatic mutation consistently present in all samples. Complex segmental aneuploidies, such as whole-genome doubling, were present in a subset of samples from the same individual, with divergent copy number changes segregating independently of point mutation acquisition. Reconstruction of evolutionary histories showed one patient with mixed HGSC and endometrioid histology, with common aetiologic origin in the fallopian tube and subsequent selection of different driver mutations in the histologically distinct samples. In this patient, we observed mixed cell populations in the early fallopian tube lesion, indicating that diversity arises at early stages of tumourigenesis. Our results revealed that HGSCs exhibit highly individual evolutionary trajectories and diverse genomic tapestries prior to therapy, exposing an essential biological characteristic to inform future design of personalized therapeutic solutions and investigation of drug-resistance mechanisms.
Collapse
Affiliation(s)
- Ali Bashashati
- Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Kommoss S, Gilks CB, Kommoss F, Chow C, Hilpert F, du Bois A, Köbel M, Huntsman DG, Anglesio M, Kalloger SE, Pfisterer J. Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. Histopathology 2013; 63:704-12. [PMID: 24033430 DOI: 10.1111/his.12219] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Accepted: 06/29/2013] [Indexed: 11/28/2022]
Abstract
AIMS The recent recognition that ovarian carcinoma is composed of five distinct disease entities has served to increase the value of accurate histotyping. Reliable identification of histotypes is essential for the success of studies testing novel therapies, as well as for biomarker discovery research. The aim of this study was to examine the utility of a nine-marker immunohistochemical (IHC) panel, designated the Calculator for Ovarian Subtype Prediction (COSP), to reliably reproduce the consensus diagnosis of two expert gynaecological pathologists. METHODS AND RESULTS A total of 423 cases from the AGO-OVAR11 trial were evaluated using the COSP IHC panel, and compared to original diagnoses from >100 local contributing pathologists and independent expert gynaecopathology review. The overall concordance between COSP and expert review was 89%; in cases where a local pathologist's diagnosis was confirmed by COSP, the expert gynaecopathologist also agreed in 97.5% of cases. CONCLUSIONS The incorporation of COSP into a high-throughput diagnostic review algorithm will decrease the need for expert review by identifying a small number of difficult cases that truly require expert review. This modification will serve to increase the efficiency of the diagnostic review process, which will probably serve to reduce operational costs and expedite translational studies on ovarian carcinoma.
Collapse
Affiliation(s)
- Stefan Kommoss
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Department of Gynecology and Obstetrics, Tuebingen University, Tuebingen, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Spowart JE, Townsend KN, Huwait H, Eshragh S, West NR, Ries JN, Kalloger S, Anglesio M, Gorski SM, Watson PH, Gilks CB, Huntsman DG, Lum JJ. The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer. J Pathol 2012; 228:437-47. [DOI: 10.1002/path.4090] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2012] [Revised: 07/15/2012] [Accepted: 07/28/2012] [Indexed: 11/07/2022]
Affiliation(s)
- Jaeline E Spowart
- Deeley Research Centre, BC Cancer Agency; Victoria BC Canada
- Department of Biochemistry and Microbiology; University of Victoria; BC Canada
- Canadian Institutes of Health Research Team in Investigating Autophagy Proteins as Molecular Targets for Cancer Treatments; Simon Fraser University; BC Canada
| | - Katelin N Townsend
- Deeley Research Centre, BC Cancer Agency; Victoria BC Canada
- Department of Biochemistry and Microbiology; University of Victoria; BC Canada
| | - Hassan Huwait
- Anatomical Pathology; Vancouver General Hospital; BC Canada
| | - Sima Eshragh
- Department of Pathology and Laboratory Medicine; University of British Columbia; BC Canada
| | - Nathan R West
- Deeley Research Centre, BC Cancer Agency; Victoria BC Canada
- Department of Biochemistry and Microbiology; University of Victoria; BC Canada
| | - Jenna N Ries
- Deeley Research Centre, BC Cancer Agency; Victoria BC Canada
- Department of Biochemistry and Microbiology; University of Victoria; BC Canada
| | - Steve Kalloger
- Department of Pathology and Laboratory Medicine; University of British Columbia; BC Canada
| | - Michael Anglesio
- Department of Pathology and Laboratory Medicine; University of British Columbia; BC Canada
| | - Sharon M Gorski
- Canadian Institutes of Health Research Team in Investigating Autophagy Proteins as Molecular Targets for Cancer Treatments; Simon Fraser University; BC Canada
- Genome Sciences Centre; BC Cancer Agency; Vancouver BC Canada
- Department of Molecular Biology and Biochemistry; Simon Fraser University; BC Canada
| | - Peter H Watson
- Deeley Research Centre, BC Cancer Agency; Victoria BC Canada
- Department of Biochemistry and Microbiology; University of Victoria; BC Canada
- Department of Pathology and Laboratory Medicine; University of British Columbia; BC Canada
| | - C Blake Gilks
- Department of Pathology and Laboratory Medicine; University of British Columbia; BC Canada
| | - David G Huntsman
- Centre for Translational and Applied Genomics, BC Cancer Agency; Vancouver BC Canada
| | - Julian J Lum
- Deeley Research Centre, BC Cancer Agency; Victoria BC Canada
- Department of Biochemistry and Microbiology; University of Victoria; BC Canada
- Canadian Institutes of Health Research Team in Investigating Autophagy Proteins as Molecular Targets for Cancer Treatments; Simon Fraser University; BC Canada
| |
Collapse
|
25
|
Hunter S, Gorringe K, Anglesio M, Sharma R, Gilks B, deFazio A, Huntsman D, Campbell I. Benign serous ovarian tumour: a redefining moment? Hered Cancer Clin Pract 2012. [PMCID: PMC3327265 DOI: 10.1186/1897-4287-10-s2-a83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
26
|
Abstract
Cancer profiling studies have had a profound impact on our understanding of the biology of cancers in a number of ways, including providing insights into the biological heterogeneity of specific cancer types, identification of novel oncogenes and tumor suppressors, and defining pathways that interact to drive the growth of individual cancers. Several large-scale genomic studies are underway that aim to catalog all biologically significant mutational events in each cancer type, and these findings will allow researchers to understand how mutational networks function within individual tumors. The identification of molecular predictive and prognostic tools to facilitate treatment decisions is an important step for individualized patient therapy and, ultimately, in improving patient outcomes. Whereas there are still significant challenges to implementing genomic testing and targeted therapy into routine clinical practice, rapid technological advancements provide hope for overcoming these obstacles.
Collapse
Affiliation(s)
- Prue A Cowin
- Peter MacCallum Cancer Center, East Melbourne, Australia 3002.
| | | | | | | |
Collapse
|
27
|
Helland A, Anglesio M, Johnstone C, George J, Cowin P, Bowtell D. 1021 A dysregulated pathway underlying a novel molecular subtype of ovarian cancer. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70314-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|